IceCure Medical's ProSense Featured in Breast Cancer Studies
Ticker: ICCM · Form: 6-K · Filed: Mar 18, 2025 · CIK: 1584371
Sentiment: neutral
Topics: medical-device, press-release, oncology
TL;DR
IceCure's cryoablation tech showcased in 6 breast cancer studies at St. Gallen conference.
AI Summary
On March 18, 2025, IceCure Medical Ltd. announced that its ProSense® Cryoablation system was featured in six studies presented at the St. Gallen International Breast Cancer Conference. The company furnished a press release detailing this information as Exhibit 99.1 with its Form 6-K filing.
Why It Matters
The inclusion of IceCure's technology in multiple studies at a prominent breast cancer conference highlights its potential role in cancer treatment and could influence future clinical adoption.
Risk Assessment
Risk Level: low — This filing is an informational report of a press release and does not contain new financial or operational disclosures that would immediately impact risk.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and subject of the press release
- ProSense® (product) — Cryoablation system featured in studies
- St. Gallen International Breast Cancer Conference (event) — Conference where studies were presented
FAQ
What is the specific title of the press release furnished by IceCure Medical Ltd.?
The press release is titled 'IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference.'
On what date was this Form 6-K filed?
The Form 6-K was filed on March 18, 2025.
What is the Commission File Number for IceCure Medical Ltd.?
The Commission File Number is 001-40753.
Which product of IceCure Medical Ltd. was featured in the studies?
The ProSense® Cryoablation system was featured in the studies.
What type of report is this filing?
This filing is a Report of Foreign Private Issuer on Form 6-K.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 18, 2025 regarding IceCure Medical Ltd. (ICCM).